TIMUR TUNCALI

Prof. Dr. TIMUR TUNCALI

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2006 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
PBPinar Bayrak-Toydemir
Pinar Bayrak-Toydemir
JMJamie McDonald
Jamie McDonald
NANurten Akarsu
Nurten Akarsu
RTReha Toydemir
Reha Toydemir
FCFernanda Calderon
Fernanda Calderon
RMRong Mao
Rong Mao

11 November 2006 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
NTNuran Turkcapar
Nuran Turkcapar
TTTIMUR TUNCALI
TIMUR TUNCALI
SKSim Kutlay
Sim Kutlay
BBBasak Yalcin Burhan
Basak Yalcin Burhan
GKGulay Kinikli
Gulay Kinikli
MDMurat Duman
Murat Duman

1 March 2004 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
SÖSuzan Özer
Suzan Özer
AUAylin Uluşahin
Aylin Uluşahin
SUSemra Ulusoy
Semra Ulusoy
HOHamza Okur
Hamza Okur
TCTurgay Coşkun
Turgay Coşkun
AAA.Nurten Akarsu
A.Nurten Akarsu

16 March 2018 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
CDCeren D. Durmaz
Ceren D. Durmaz
D. Gareth EvansD. Gareth Evans
D. Gareth Evans
MSMiriam J. Smith
Miriam J. Smith
PEPelin Ertop
Pelin Ertop
BABengu Nisa Nisa Akay
Bengu Nisa Nisa Akay
TTTIMUR TUNCALI
TIMUR TUNCALI
Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a rare multisystemic autosomal dominant disorder typically presenting with cutaneous basal cell carcinomas, multiple keratocysts, and skeletal anomalies. NBCCS is caused by heterozygous mutations in the PTCH1 gene in chromosome 9q22, in the PTCH2 gene in 1p34, or the SUFU gene in 10q24.32. Here, we report on an 18-month-old boy presenting with medulloblastoma, frontal bossing, and multiple skeletal anomalies and his father who has basal cell carcinomas, palmar pits, macrocephaly, bifid ribs, calcification of falx cerebri, and a history of surgery for odontogenic keratocyst. These clinical findings were compatible with the diagnosis of NBCCS, and a novel mutation, c.1249delC; p.Gln417Lysfs*15, was found in PTCH1 causing a premature stop codon.

23 September 2011 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
FEF. Ekiz
F. Ekiz
NON. Ormeci
N. Ormeci
SCS. Coban
S. Coban
HKH. G. Karabulut
H. G. Karabulut
BAB. Aktas
B. Aktas
NAN. Alkış
N. Alkış

1 March 2014 in Turkish Journal of Hematology
Verified
Journal Article
Open access
ŞÖŞule Mine Bakanay Öztürk
Şule Mine Bakanay Öztürk
GKGülşah Kaygusuz
Gülşah Kaygusuz
PTPervin Topçuoğlu
Pervin Topçuoğlu
ŞŞŞule Şengül
Şule Şengül
TTTIMUR TUNCALI
TIMUR TUNCALI
MAMutlu Arat
Mutlu Arat
Three cases of Epstein-Barr virus (EBV)-negative post-transplant lymphoproliferative disease that occurred 6 to 8 years after renal transplantation are reported. The patients respectively had gastric mucosa-associated lymphoid tissue lymphoma, gastric diffuse large B-cell lymphoma, and atypical Burkitt lymphoma. Absence of EBV in the tissue samples was demonstrated by both in situ hybridization for EBV early RNA and polymerase chain reaction for EBV DNA. Patients were treated with reduction in immunosuppression and combined chemotherapy plus an anti-CD20 monoclonal antibody, rituximab. Despite the reduction in immunosuppression, patients had stable renal functions without loss of graft functions. The patient with atypical Burkitt lymphoma had an abnormal karyotype, did not respond to treatment completely, and died due to disease progression. The other patients are still alive and in remission 5 and 3 years after diagnosis, respectively. EBV-negative post-transplant lymphoproliferative diseases are usually late-onset and are reported to have poor prognosis. Thus, reduction in immunosuppression is usually not sufficient for treatment and more aggressive approaches like rituximab with combined chemotherapy are required.\u